Join Omixon for our Very First User Group Meeting at EFI 2018!

07/02/2018

The Omixon User Group Meeting being held on Wednesday, May 9th, 2018 at 1- 5pm CET at the EFI Annual Meeting in Venice, Italy. The User Group Meeting will be a forum not only for us to provide you with the most recent Holotype HLA v2.2 product updates, but...

MHC-I Genotypes Influence Cancer Susceptibility

01/02/2018

Cancer research has gone through a process of development in the last thirty years due to the growth in the field of genetics. Before the advent of genomic testing, most individuals with a certain type and stage of cancer received the same chemotherapy, but these treatments had variable outcomes....

A Letter from Omixon CEO, Dr. Peter Meintjes

30/01/2018

Dear Customers and Friends of Omixon, 2017 was one heck of a year – a year filled with growth and change; the year the Orville Omixon took flight to unchartered territories (and beyond?). Back in January 2017 we moved our company offices for the second time in our history,...

Omixon HLA Twin RUO 2.5.0 New Release

29/01/2018

We are excited to announce a release for HLA Twin RUO version 2.5.0. – the world’s most accurate, high throughput HLA genotyping software. Here is the list of new features and improvements: New features and improvements Holotype HLA v2 kit support: Assay version selector allows user to select the...

A Brief History of Xenotransplantation

17/01/2018

Transplantation has been one of the most challenging areas of modern medicine. Since there are more patients awaiting a transplant than available organs, the waiting list is growing exponentially each year . Xenotransplantation, the transplantation of animal organs into humans, has long been appealing as a possible solution for...